Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | C1S | P09871 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7769861 | 0.81 | ABAT (0.48) | LOXL2CA2MAPT | |
| SCHEMBL5272776 | 0.80 | GFER (0.50) | GFERALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL1331730 | 0.78 | CA2 (0.62) | GFERALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL687483 | 0.78 | CA2 (0.67) | GFERALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL11212239 | 0.78 | CA2 (0.62) | ALDH1A1TSHRTDP1CA2MAPT | |
| SCHEMBL3424224 | 0.78 | PRSS1 (0.43) | TSHRCA2PRSS1PRSS2PRSS3 | |
| SCHEMBL39103 | 0.78 | CA2 (0.62) | GFERALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL4044552 | 0.78 | CA2 (0.62) | ALDH1A1CA2MEN1KMT2ARAB9A | |
| SCHEMBL5498931 | 0.77 | GFER (0.54) | GFERALDH1A1CYP3A4TSHRTDP1 | |
| Bromide SCHEMBL25328791 | 0.76 | CA2 (0.60) | GFERALDH1A1CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768978-B1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| US-20080058332-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-5885787-A | Process for preparing optically active amines | BAYER AKTIEGESELLSCHAFT (DE) | 1999-03-23 | — | — | US | disclosed |
| EP-0812363-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE AMINES | BAYER AG (DE) | 1997-12-17 | — | — | EP | disclosed |
| WO-1996027022-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-09-06 | — | — | WO | disclosed |
| EP-0399589-A1 | Preparation of N-acyl alkylamines | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1990-11-28 | — | — | EP | disclosed |
| US-4282145-A | Process for the preparation of azetidines | GIST-BROCADES N.V. (NL) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058332-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PIK3CA, TYMP, PIK3CB | GFER 4862/4885ALDH1A1 2649/4885CYP3A4 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.